Answers are grounded in this paper and cite their sources.
Prior to the Food and Drug Administration approval of cemiplimab in 2018, the median overall survival (OS) for adult patients with advanced CSCC receiving systemic therapy was approximately 8 to 15 months. Limited real-world data are available on cemiplimab for this indication in the US.
No takes yet. Share an insight, caveat, or question.
Ge et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: